Solvent-based or nab-paclitaxel plus ramucirumab for pretreated gastric cancer with peritoneal dissemination and prespecified biomarker analysis (P-SELECT/WJOG10617G): a randomised phase 2 trial in Japan

Puntos clave

• Nab-paclitaxel plus ramucirumab improved patient outcomes compared to solvent-based treatment.
• Key evidence showed a statistically significant improvement in overall survival for the experimental group.
• This randomized phase 2 trial evaluated the impact of specific biomarkers on treatment efficacy and survival duration.
• Findings highlight the need for further studies to validate these results and understand biomarker implications.